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Abstract 
Given the relationship between sleep and depression, there is inevitably going to be an effect of antidepressants on 
sleep. Current evidence suggests that this effect depends on the class of antidepressant used and the dosage. The extent 
of variation between the effects of antidepressants and sleep may relate to their mechanism of action. This systematic 
review examines randomised-controlled trials (RCTs) that have reported the effect that antidepressants appear to have 
on sleep. RCTs are not restricted to depressed populations, since several studies provide useful information about the 
effects on sleep in other groups. Nevertheless, the distinction is made between those studies, because the participant’s 
health may influence the baseline sleep profiles and the effect of the antidepressant. Insomnia is often seen with 
monoamine oxidase inhibitors (MAOIs), with all tricyclic antidepressants (TCAs) except amitriptyline, and all selective 
serotonin reuptake inhibitors (SSRIs), as well with venlafaxine and moclobemide. Sedation has been reported with all 
TCAs except desipramine, with mirtazapine and nefazodone, the TCA-related maprotiline, trazodone and mianserin, 
and with all MAOIs. REM sleep suppression has been observed with all TCAs except trimipramine, but especially 
clomipramine, with all MAOIs and SSRIs and with venlafaxine, trazodone and bupropion. However, the effect on sleep 
varies between compounds within antidepressant classes, differences relating to the amount of sedative or alerting 
(insomnia) effects, changes to baseline sleep parameters, differences relating to REM sleep, and the degree of sleep-
related side effects.  
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Review method 
The review exercise was undertaken by exploring the Ovid
®
 database, searching the CINAHL 
(1982 - May 2005), EMBASE (1980 – May 2005), Ovid MEDLINE® (1966 – May 2005) and 
PsychINFO (1985 – May 2005). A search strategy was undertaken to improve the likelihood of 
including high quality randomised controlled-trials (RCTs) that used a double-blind randomisation 
of participants into groups of at least 5 (per group), included in a baseline and follow-up 
examination of the effect of antidepressants on sleep, where those antidepressants were compared to 
placebo (placebo-controlled trials) and/or to other antidepressants (comparator trials). Papers were 
selected regardless of the nature of the participants. Antidepressant effects on sleep may vary with 
the current health of the participant and it is important to make that distinction. Careful 
consideration is also paid to the dose of antidepressant as that may explain some of the variation 
between studies in similar participant groups. A more general overview is also presented on the 
mechanisms of action of differing classes of antidepressants that might explain the effect they 
appear to have on sleep. 
 
Following exclusions, 120 papers were examined, 53 of which included placebo. Those papers are 
presented in Table 1. The following section presents general findings for each antidepressant class, 
and indicates the mechanisms that might be responsible for those effects. Within each class some of 
the more specific findings for each antidepressant are examined. Rather than duplicate the data from 
Table 1, only the most important aspects are described.  
 
Pharmacological overview 
Several mechanisms are important in the effects of antidepressant treatment on sleep. Increases in 
the availability of serotonin and noradrenaline appear to be associated with the suppression of REM 
sleep, but also with increases in sleep fragmentation (Wilson and Argyropoulos, 2005). The 
pathways responsible for these actions vary across antidepressant class and with individual 
  4 
medications, but generally refer to action on pre-synaptic autoreceptors, post-synaptic 5HT receptor 
sites (such as the 5-HT1A and 5-HT2 receptors), α1- and α2-adrenoceptors and histamine H1 
receptors. 5-HT1A stimulation may be associated with REM sleep suppression; 5-HT2 agonism may 
be related to sleep disturbance. Inhibition of α2-adrenoceptors autoreceptors increases availability of 
noradrenaline, and therefore may be associated with fragmentation of sleep. Blockade of the other 
receptor sites (α1-adrenoceptors and histamine H1) may facilitate sleep promotion (Wilson and 
Argyropoulos, 2005).  
 
Tricyclic Antidepressants (TCAs) 
There is much variation between TCAs in the effect on sleep architecture, and with regard to 
sedating and alerting properties. The British Association for Psychopharmacology (BAP) guidelines 
(Anderson et al., 2000) suggest that sedation is ‘relatively common or strong’ with amitriptyline, 
dothiepin and clomipramine, while this ‘may occur or is moderately strong’ with imipramine, 
desipramine and nortriptyline. Sedation may be useful in depressed patients with insomnia, but 
might not be welcome in those patients wishing to avoid daytime sleepiness.  
 
The mechanisms thought to be responsible for sleep effects in TCAs vary with specific compounds. 
Most TCAs inhibit the reuptake of both serotonin and noradrenaline, but the relative extent that they 
do this varies, and may explain some of the differences in sedation and REM sleep suppression. All 
TCAs except lofepramine block histamine H1 receptors, and all but desipramine block α1-
adrenoceptors. The blockade of histamine H1 receptors may be related to sleep promotion (Haas and 
Panula, 2003), but the evidence for an effect on REM sleep or SWS is weak (Wilson and 
Argyropoulos, 2005). Antagonism of α1-adrenoceptors is more likely to explain the sedative 
properties of TCAs, as might the 5-HT2 blockade action, as seen with amitriptyline and 
trimipramine (which are particularly associated with sedation).  
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Amitriptyline 
Depressed patients 
(Staner et al., 1995) found that amitriptyline (150mg) produced more alerting effects than 
paroxetine (30mg). (Kerkhofs et al., 1990) demonstrated that amitriptyline (150mg) and fluoxetine 
(60mg) both produced significant REM sleep suppression. (Casper et al., 1994) showed that 
patients presented better improvement in early morning awakening, and nocturnal wakings with 
amitriptyline (100-150mg) than imipramine (100-150mg); although this was only for those who had 
responded to treatment. (Kerr et al., 1993) observed that amitriptyline (75mg) was associated with 
significantly shorter sleep latency, but more drowsiness, than fluoxetine (20mg) on the Line 
Analogue Rating Scale for Sedation (LARS) scale. However (De Ronchi et al., 1998) found no 
between-group differences for patients in respect of Leeds Sleep Evaluation (LSEQ) scores between 
amitriptyline (50-100mg) and fluoxetine (20mg).  
 
Other patient groups 
(Mertz et al., 1998) found that amitriptyline (50mg) reduced REM sleep in gastroenterology 
patients, compared to placebo, while (Carette et al., 1995) demonstrated fewer changes in REM 
sleep parameters in fibromyalgia patients (dosage, 25mg). This is just one example where the dose 
may be a significant factor in contrasting findings. For fibromyalgia patients (Hannonen et al., 
1998), subjective sleep ratings were significantly improved from baseline with amitriptyline (25-
37.5mg), compared to placebo. In a study of cancer patients with neuropathic pain (Mercadante et 
al., 2002), it was found that drowsiness was significantly higher with amitriptyline (25-30mg) than 
placebo. In another study (Mertz et al., 1998), amitriptyline (50mg) was associated with poorer 
sleep efficiency for patients with functional dyspepsia, compared to placebo. In a study of patients 
with chronic pain (Versiani et al., 1999), amitriptyline (50-250mg) was associated with better 
improvements in Hamilton Rating Scale for Depression (HAMD; (Hamilton, 1960)) sleep scores 
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than fluoxetine (20mg), although daytime drowsiness was a significantly greater problem with 
amitriptyline. 
 
Healthy participants 
(Rosenzweig et al., 1998) found that subject-rated alertness and behaviour upon waking was 
significantly poorer with amitriptyline (50mg) than placebo. This hangover effect was confirmed by 
(Hindmarch et al., 2000) who demonstrated that sedation and trouble waking were significantly 
worse for amitriptyline (50mg), compared to placebo.  
 
Clomipramine 
Clomipramine may be associated with sedation, but has also been linked with insomnia (Anderson 
et al., 2000). While most TCAs suppress REM sleep to some extent, clomipramine appears to be 
the most marked in this respect (Winokur et al., 2001).  Clomipramine is associated with the most 
potent serotonin reuptake inhibition of all the TCAs (Wilson and Argyropoulos, 2005).  
 
Depressed patients 
(Lepine et al., 2000) demonstrated no differences between clomipramine (50-150mg) and sertraline 
(50-200mg) on LSEQ and HAMD sleep scores, but both showed significant improvements on all 
four LSEQ factors (Ease of getting to sleep (EGS); perceived quality of sleep (QOS); ease of 
awakening (EOA); and behaviour following wakefulness (BFW)).  
 
Healthy participants 
(Lacey et al., 1977) found that clomipramine (25-75mg) was associated with slightly longer 
nocturnal awakenings than placebo, and almost completely suppressed REM sleep.  
 
Imipramine 
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Depressed patients 
(Sonntag et al., 1996) demonstrated that imipramine (50-200mg) significantly increased sleep 
latency, while trimipramine (50-250mg) was associated with a non-significant decrease; imipramine 
was associated with significantly less total sleep time, and significantly more nocturnal awakenings 
than trimipramine. (Volkers et al., 2002) found that imipramine (mean dose 220mg) was associated 
with significantly more nocturnal restlessness than fluvoxamine (mean 201mg).  
 
Other patient groups 
In a study of patients reporting panic disorder or agoraphobia, (Cassano et al., 1994) imipramine 
(25-250mg) was associated with more sedation than placebo (although less than alprazolam; 1-
10mg), but significantly more insomnia than placebo and alprazolam. (Sonntag et al., 1996) found 
that imipramine (50-200mg) was associated with decreased total sleep time, while this was 
increased with trimipramine (50-250mg); sleep efficiency was significantly more improved with 
trimipramine but wakings were significantly more frequent with imipramine.  
 
Trimipramine 
Depressed patients 
(Wolf et al., 2001) showed that trimipramine (150mg) was associated with improved sleep 
efficiency, longer sleep, and fewer nocturnal arousals, compared to fluoxetine (20mg). 
 
Other patient groups 
(Riemann et al., 2002) found that trimipramine (mean 100mg) was not associated with REM sleep 
suppression, when compared to placebo with insomnia patients. Unlike other TCAs, which are 
associated with REM suppression, trimipramine is not associated with the reuptake inhibition of 
serotonin (Wilson and Argyropoulos, 2005). 
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Desipramine 
Depressed patients 
(Kupfer et al., 1991) demonstrated that desipramine (100-200mg) significantly reduced sleep 
latency after just one day of treatment, but this significantly increased again within a week and 
throughout the remainder of the 4-week study. Desipramine was associated with shorter sleep 
latency than fluvoxamine (200mg), and presented better sleep efficiency. In another study (Shipley 
et al., 1985), desipramine (50-250mg) was associated with more nocturnal waking, shorter sleep, 
and less efficient sleep than amitriptyline (50-150mg). Unlike other TCAs, desipramine is not 
associated with α1-adrenoceptor blockade (Wilson and Argyropoulos, 2005), which may explain 
why it does not promote sleep as well. It is also associated with less serotonin reuptake inhibition 
than most other TCAs.  
 
Nortriptyline 
Depressed patients 
(Reynolds, III et al., 1997) demonstrated that nortriptyline (80-120mg) was associated with longer 
sleep latency than placebo. Nortriptyline also showed initial suppression of REM sleep, with 
prolonged REM latency and reduced REM proportion, but this rebounded in later REM periods to 
show greater REM production and density than placebo.  
 
Other patient groups 
In a study of patients with skin complaints (Hammack et al., 2002), total sleep time improved for 
those treated with nortriptyline (100mg), compared to placebo. However, daytime sleepiness was 
reported as a problem in the treatment group. 
 
Dothiepin 
Depressed patients 
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(Stephenson et al., 2000) demonstrated that drowsiness side effects were more common with 
dothiepin (150mg) than fluoxetine (20mg). (Ferguson et al., 1994) found that HAMD sleep scores 
were significantly reduced with dothiepin (150mg), compared to placebo (but were similar to 
doxepin). (Blacker et al., 1988) showed that dothiepin (75-150mg) was associated with more 
immediate improvement of EGS and QOS perceptions on LSEQ than amitriptyline (75-100mg) or 
mianserin (30-75mg), although was similar to trazodone (150mg). LSEQ perceptions of BFW were 
poor during the first week for all the comparator compounds, but improved thereafter.  
 
Healthy participants 
(Ramaekers et al., 1995) found that dothiepin (75-150mg) was associated with increased trouble in 
waking, but longer total sleep time than placebo. (Wilson et al., 2002) demonstrated that dothiepin 
(75-150mg) was associated with poorer sleep efficiency than placebo (and fluoxetine 20mg), but 
shorter nocturnal awakenings than fluoxetine; REM sleep latency was significantly shorter for 
dothiepin than for fluoxetine. (Wilson et al., 2000) showed that dothiepin (100mg) was associated 
with longer TST, shorter nocturnal disturbances, better sleep efficiency, and better sleep quality 
than fluvoxamine (100mg).  
 
Doxepin 
Depressed patients 
(Ferguson et al., 1994) found that clinician-rated HAMD sleep scores were significantly reduced 
with doxepin (150mg), compared to placebo, while (Feighner et al., 1986) showed that doxepin 
(100-225mg) was related to significantly better improvements on these scores than bupropion (300-
450mg). 
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Other patient groups 
Sleep efficiency and sleep quality were significantly improved for insomnia patients taking doxepin 
(25-50mg), compared to placebo (Hajak et al., 2001), while doxepin (25mg) was associated with 
significantly increased total sleep time, and significantly reduced sleep latency and length of 
nocturnal awakenings, compared to placebo with insomnia patients and healthy volunteers (Hajak et 
al., 1996).  
 
Monoamine oxidase inhibitors (MAOIs) 
MAOIs have been associated with increased sleep latency, poorer sleep efficiency, and increased 
nocturnal disturbances (Winokur et al., 2001). Insomnia has been reported for phenelzine, 
tranylcypromine and isocarboxazid (Anderson et al., 2000), while significant REM sleep 
suppression has been noted with phenelzine and tranylcypromine (Winokur et al., 2001). However, 
REM rebound is noted subsequent to the withdrawal of medication (Kupfer and Bowers Jr, 1972). 
There is a paucity of RCTs with MAOIs. Moclobemide, a reversible MAOI, has been associated 
with less REM sleep suppression than traditional MAOIs (Winokur et al., 2001). Sedation is not 
reported with moclobemide, although minor insomnia has been noted (Anderson et al., 2000). 
MAOIs increase the availability of monoamines, but REM suppression often appears later than with 
TCAs and SSRIs (Wyatt et al., 1971).  
 
Tranylcypromine 
Depressed patients 
(Nolen et al., 1993) found that tranylcypromine (20-100mg) significantly increased REM sleep 
latency and almost completely suppressed REM sleep overall. Sleep latency was also increased, but 
patients reported deeper and more refreshed sleep than with brofaromine (50-250mg).  
 
Isocarboxazid 
  11 
Depressed patients 
(Giller et al., 1982) demonstrated that isocarboxazid (20mg) did not differ from placebo on HAMD 
sleep scores, but treatment responders tended to sleep better overall with isocarboxazid than with 
placebo.  
 
Moclobemide 
Depressed patients 
(Sogaard et al., 1999) found that moclobemide (300-450mg) was associated with poorer BFW 
scores on LSEQ than sertraline, while sleep was observed to better with moclobemide (450mg) than 
with toloxatone (100mg; (Lemoine and Mirabaud, 1992)).  
 
Other patient groups 
(Hannonen et al., 1998) demonstrated that moclobemide (450-600mg) was associated with poorer 
subjective sleep satisfaction and fatigue (not assessed with a specific scale) than amitriptyline (25-
37.5mg) in patients with fibromyalgia.  
 
Healthy participants 
Two trials involving moclobemide with healthy participants ((Dingemanse et al., 1992), 450mg; 
(Ramaekers et al., 1992), 200mg) suggest that moclobemide has no effect on sleep, when compared 
to placebo or other antidepressants.  
 
Selective serotonin reuptake inhibitors (SSRIs) 
SSRIs are frequently associated with insomnia (Anderson et al., 2000); around one-quarter of 
depressed patients in clinical trials report insomnia (Winokur et al., 2001). Less well documented is 
that SSRIs may cause daytime somnolence, particularly at higher doses (Beasley Jr  et al., 1992). 
EEG studies of sleep confirm that SSRIs immediately suppress REM sleep, and continue to do so 
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throughout treatment; REM parameters return to normal once the SSRI is discontinued (Winokur et 
al., 2001).  
 
The observed effects on sleep of SSRIs are thought to be due to the effects of increased levels of on 
5-HT1A and 5-HT2 receptors. Activation of 5-HT1A receptors is probably responsible for REM 
suppression (Gillin et al., 1994), but is unlikely to mediate sleep fragmentation. This is more likely 
to be due to stimulation of 5-HT2 receptors (Lawlor et al., 1991). By definition, SSRIs block 
serotonin reuptake, but some also block noradrenaline reuptake. Both actions have been associated 
with REM suppression and sleep disruption (Wilson and Argyropoulos, 2005).  
 
Citalopram 
Depressed patients 
(Mendels et al., 1999) found that citalopram (20-80mg) was associated with significant 
improvements in HAMD sleep scores, relative to placebo; although daytime sleepiness was a 
significantly greater problem for those taking citalopram than for placebo. (Rosenberg et al., 1994) 
demonstrated that citalopram (10-60mg) was associated with significantly better HAMD sleep 
scores (from baseline), but did not differ from imipramine (50-100mg). (Leinonen et al., 1999) 
showed that subjective ratings for all LSEQ factors significantly improved with citalopram (20-
60mg), although not as quickly as with mirtazapine (15-60mg).  
 
Escitalopram 
Escitalopram is a relatively new antidepressant in the SSRI class. It has been developed from one of 
the isomers of citalopram, so whilst chemically identical, it may be more beneficial than citalopram 
if the efficacy elements reside in that single isomer; it may also possess less side effects than the 
original combination. There are currently no RCTs that specifically examine escitalopram in 
placebo or comparator trials. In a recent pooled analysis (Lader et al., 2005), which compares data 
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from RCTs involving citalopram and escitalopram, it was shown that escitalopram (10-20mg) 
showed significantly better improvements on the Montgomery-Asberg Depression Rating Scale 
(MADRS; Montgomery and Åsberg, 1979) item 4 (sleep) at all time points (weeks 1, 4, 6 & 8); 
citalopram (20-40mg) was only significantly better at week 6. The proportion of patients with sleep 
problems (at baseline MADRS item 4 ≥ 4) improving by endpoint (MADRS item 4 ≤ 1) was 
significantly higher with escitalopram than citalopram. However, prospective RCTs specifically 
examining sleep are required. 
 
Sertraline 
Depressed patients 
(Jindal et al., 2003) found that sertraline (mean 142mg) suppressed REM sleep and increased sleep 
latency (although not significantly), compared to placebo. (Lepine et al., 2000) showed that 
sertraline (50-200mg) and clomipramine (50-150mg) significantly improved LSEQ (all factors) and 
HAMD sleep scores, but there were no between-group differences. (Bennie et al., 1995) 
demonstrated that sertraline (50-100mg) was associated with fewer reports of trouble in sleep 
initiation than fluoxetine (20-40mg), but with poorer perceptions on waking. Although overall 
LSEQ scores were significantly improved for both groups, they differed on individual items: 
sertraline showed better EGS scores than fluoxetine, but poorer EOA and BFW.  
 
Healthy participants 
(Paul et al., 2002) found that sertraline (50-150mg) was associated with significantly more 
insomnia than with placebo. 
 
 
Fluoxetine 
Depressed patients 
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(Rush et al., 1998) found that sleep was significantly less efficient, and nocturnal awakenings were 
significantly greater, with fluoxetine (20-40mg) when compared to nefazodone (100-500mg). 
Fluoxetine significantly suppressed REM sleep, while nefazodone significantly increased the time 
spent in REM sleep. (Wolf et al., 2001) demonstrated that fluoxetine (20mg) was associated with 
less efficient, shorter and more disrupted sleep than trimipramine (150mg); fluoxetine suppressed 
REM sleep, whereas trimipramine did not. (Satterlee and Faries, 1995) showed that HAMD sleep 
scores tended to show better improvement for fluoxetine (20mg) than placebo, but this was not 
significant. (Winokur et al., 2003) found no differences between fluoxetine (20-40mg) and 
mirtazapine (15-45mg) in respect of HAMD sleep scores; both showing significant improvements. 
However, improvements in sleep latency and total sleep time were not as marked for fluoxetine as 
they were for mirtazapine, which resulted in more efficient sleep and less nocturnal disturbances 
than fluoxetine.  
 
Other patient groups 
(Wolfe et al., 1994) found that self-reported sleep quality perceptions were significantly better with 
fluoxetine (20mg) than placebo for patients with fibromyalgia. 
 
Healthy participants 
(Vasar et al., 1994) demonstrated that fluoxetine (20mg) increased REM sleep latency and reduced 
overall REM proportion, increased sleep stages 2 and 3, increased sleep latency and worsened sleep 
efficiency, compared to placebo.  
 
Fluvoxamine 
Depressed patients 
(Volkers et al., 2002) found that fluvoxamine (mean 201mg) was associated with more fragmented 
sleep than imipramine (mean 220mg), while (Kupfer et al., 1991) demonstrated greater sleep 
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disruption for fluvoxamine (200mg) than desipramine (100-200mg). (Perez and Ashford, 1990) 
showed that fluvoxamine (100-300mg) was associated with poorer EGS ratings on the LSEQ than 
mianserin (60-180mg) but fluvoxamine was related to better BFW ratings. While fluvoxamine 
(100mg) and fluoxetine (20mg) did not differ in their effect on sleep in the first month of treatment, 
after that HAMD sleep scores were significantly better for fluvoxamine (Dalery and Honig, 2003).  
 
Healthy participants 
(Silvestri et al., 2001) found that fluvoxamine (100mg) was less disruptive to sleep than paroxetine 
(20mg), but tended to be associated with greater REM sleep suppression. (Wilson et al., 2000) 
demonstrated that fluvoxamine (100mg) was associated with shorter and more disrupted sleep than 
with dothiepin (100mg) or placebo. Although poorer subjective sleep quality was reported for 
fluvoxamine than dothiepin, perceptions upon waking were better.  
 
Paroxetine 
Depressed patients 
(Dunbar et al., 1993) found that HAMD sleep scores were significantly more improved with 
paroxetine (10-50mg) than placebo. (Staner et al., 1995) showed that paroxetine (30mg) was more 
alerting than amitriptyline (150mg). Sleep quality was rated significantly more poorly with higher 
doses of paroxetine (40mg vs. 20mg) than with amitriptyline (75mg) or placebo (Robbe and 
O'Hanlon, 1995). (Schatzberg et al., 2002) demonstrated that HAMD sleep scores were poorer with 
paroxetine (20-40mg) than mirtazapine (15-45mg). (Hicks et al., 2002) found that sleep time was 
less, and disruption greater, for paroxetine (20-40mg) compared to nefazodone (400-600mg). REM 
sleep was shown to be significantly more suppressed with paroxetine than nefazodone, and 
subjective sleep ratings showed greater improvements with nefazodone. 
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(Dorman, 1992) demonstrated that LSEQ scores were significantly more likely to be improved with 
paroxetine (15mg) than mianserin (30mg); paroxetine was significantly improved from baseline on 
all four factors; mianserin only for BFW. In an RCT where the time of dose was randomised (Wade 
and Aitken, 1993), HAMD scores were significantly better for morning doses of paroxetine (15-
30mg) than evening doses.   
 
Other patient groups 
(Capaci and Hepguler, 2002) found that sleep disruption did not improve as well with paroxetine 
(20-40mg) as it did for amitriptyline (10-20mg) in fibromyalgia patients.   
 
Healthy participants 
(Ridout et al., 2003) demonstrated that paroxetine (20mg) was associated with longer sleep latency 
and poorer reports of sleep quality than mirtazapine (15-30mg). (Sharpley et al., 1996) observed 
greater suppression of REM sleep for paroxetine (30mg) than for nefazodone (400mg).  
 
Other antidepressants 
 
Venlafaxine 
Venlafaxine blocks the reuptake of serotonin and noradrenaline, mostly the former in lower doses 
(less than 150 mg), with little effect on post-synaptic receptor sites. Increases in these monoamines 
are related to REM suppression and sleep fragmentation (Wilson and Argyropoulos, 2005).  
 
 
 
Depressed patients 
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(Luthringer et al., 1996) found that venlafaxine (225mg) was associated with significant REM sleep 
reduction, and significantly increased nocturnal disturbance, compared to placebo. (Cunningham et 
al., 1994) demonstrated that HAMD sleep scores were improved following venlafaxine (25-
200mg), but significantly less so than with trazodone, and no different to placebo. (Guelfi et al., 
2001) showed that HAMD sleep scores were also significantly poorer for venlafaxine (75-375mg) 
than mirtazapine (15-60mg). 
 
Reboxetine 
Reboxetine inhibits the reuptake of noradrenaline, and is not associated with direct activity at post-
synaptic receptor sites. No RCTs were found in the systematic review, but one uncontrolled study 
showed evidence of transient sleep disruption, but persistent REM suppression, with 2mg (b.d.) of 
reboxetine in 12 dysthymic patients (Ferini-Strambi et al., 2004), and (Kuenzel et al., 2004) found 
nocturnal disturbance and reduced sleep efficiency with reboxetine (8-10mg) in 8 depressed 
patients.  
 
Trazodone 
Trazodone is associated with weak serotonin reuptake blockade, and with antagonist actions at α1-
adrenoceptors, 5-HT1A and 5-HT2 receptors. The effects on α1-adrenoceptor and 5-HT2 receptor sites 
may explain why there is more evidence of sleep promotion with this compound. However, 
trazodone has also shown to suppress REM sleep in some studies (Mouret et al., 1988), which 
seems at odds with the relative lack of serotonin reuptake antagonism and the inhibition of 5-HT1A 
(Wilson and Argyropoulos, 2005). The reasons for this are unclear.  
 
 
Depressed patients 
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(Mashiko et al., 1999) found that sleep scores on HAMD were significantly better improved for 
trazodone (50-100mg) than placebo, although the effect was better in lower doses. (Nierenberg et 
al., 1994) demonstrated that trazodone (50-100mg) was associated with significantly better patient-
rated sleep quality (Pittsburgh Sleep Quality Index) and clinician-rated sleep scores (Yale-New 
Haven Hospital Depression Symptom Inventory) than was placebo. (Blacker et al., 1988) observed 
better improvements in subjective sleep ratings with trazodone (150mg) than with amitriptyline (75-
100mg) or mianserin (30-75mg). (Moon and Davey, 1988) demonstrated similar improvements for 
all LSEQ scores with trazodone (150mg) and mianserin (30-60mg), although trazodone tended to 
show more rapid improvements.  
 
Other patient groups 
(Le Bon et al., 2003) showed that trazodone (100mg) was associated with significantly better sleep 
efficiency and significantly less nocturnal disturbance than placebo in alcohol dependent patients. 
(Walsh et al., 1998) found that subjective ratings of sleep initiation, nocturnal awakenings, and 
sleep quality were significantly better for trazodone (50mg) than placebo for insomnia patients, but 
did not differ from the effects of the hypnotic drug zolpidem (10mg). (Saletu-Zyhlarz et al., 2001) 
observed significantly suppressed REM sleep for trazodone (100mg), compared to placebo, in 
dysthymic insomnia patients.  
 
Healthy participants  
(Ware et al., 1994) observed significantly more REM sleep suppression with trazodone (100mg) 
than with nefazodone (200mg).  
 
Nefazodone 
Nefazodone has mild serotonin reuptake blocking properties, and stronger 5–HT2 antagonist effects. 
It is not associated with REM suppression, as might be expected (Wilson and Argyropoulos, 2005), 
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The blockade of α1-adrenoceptor sites, and the 5-HT2 receptor probably underlie the beneficial 
effects on sleep continuity that have been observed.  
 
Depressed patients 
(Feighner et al., 1998) found that nefazodone (100-600mg) was associated with significantly better 
improvements in HAMD sleep scores than placebo. Previous analyses indicated that nefazodone 
was associated with less nocturnal disturbance than fluoxetine (Rush et al., 1998) or paroxetine 
(Hicks et al., 2002). While nefazodone shows clear benefits for sleep, it is no longer available in 
many countries. 
 
Healthy participants  
In contrast to some findings in depressed groups, (Vogel et al., 1998) showed that nefazodone (200-
400mg) reduced total sleep time, and increased nocturnal awakenings, when compared to placebo, 
in 120 healthy volunteers.  
 
Mianserin 
Mianserin is an antagonist at α1-adrenoceptor sites and 5-HT2 receptors, which may promote sleep 
but also with inhibition of the α2-adrenoceptor, and with moderate inhibition of noradrenaline 
reuptake (Wilson and Argyropoulos, 2005), which may fragment sleep and suppress REM sleep. 
This compound has been associated with sleep promotion properties, particularly in comparison to 
SSRIs, as this review has shown, possibly through inhibition of histamine H1 receptors. There are 
no RCTs that explore the effects of mianserin on REM sleep, but uncontrolled studies have 
suggested slight suppression (Maeda et al., 1991).  
 
Depressed patients 
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(Smith and Naylor, 1978) found that mianserin (30mg) was associated with significantly better 
nurse-rated, and patient-rated, improvements in total sleep time than placebo. (Granier et al., 1985) 
demonstrated that mianserin (30mg) was associated with significantly better improvements in 
HAMD sleep scores than nomifensine (50mg). Mianserin (10-20mg) was associated with 
significantly reduced HAMD sleep scores compared to placebo for depressed women with cancer 
(Costa et al., 1985) However, this may have been compounded by the addition of the hypnotic drug 
nitrazepam (2.5-10mg) for those patients with persistent insomnia.  
 
Mirtazapine 
Mirtazapine blocks α2-autorecptors, 5-HT2 receptors and H1 receptors. α2-adrenoceptor inhibition 
increases noradrenaline, thus suppressing REM sleep and disrupting sleep continuity; while the 
other actions tend to promote sleep. The improvements in sleep with mirtazapine are more likely to 
be the result of 5-HT2 receptor inhibition (Haddjeri et al., 1995).  
 
Depressed patients 
(Leinonen et al., 1999) found that mirtazapine (15-60mg) was associated with more rapid 
improvements in QOS and BFW on the LSEQ than was citalopram (20-60mg). Earlier analyses 
comparing mirtazapine to other antidepressants, indicated less nocturnal disturbance and better 
sleep efficiency than with fluoxetine (Winokur et al., 2003) or paroxetine (Ridout et al., 2003), and 
better HAMD sleep scores than with paroxetine (Schatzberg et al., 2002) or venlafaxine (Guelfi et 
al., 2001). 
 
 
Healthy participants  
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(Aslan et al., 2002) demonstrated that mirtazapine (30mg) was associated with significantly greater 
improvements in sleep efficiency, including fewer nocturnal disturbances than with placebo, but did 
not affect REM sleep measures.  
 
Bupropion 
Bupropion is used as an agent to facilitate smoking cessation, and as an antidepressant in the US 
and some other countries. Its mechanism of action is not fully understood, but may involve 
noradrenaline reuptake, which is associated with REM suppression, and enhanced dopamine 
availability (Wilson and Argyropoulos, 2005), which is not. However, RCT evidence suggests that 
bupoprion is associated with REM suppression.  
 
Depressed patients 
(Ott et al., 2002) found no differences with regard to sleep measures between bupoprion (150-
400mg) and placebo, although treatment response was associated with significant REM 
suppression. 
 
Other patient groups 
(Haney et al., 2001) observed that bupropion (300mg) was associated with poorer sleep than 
placebo in patients withdrawing from marijuana; total sleep time and getting to sleep were 
particularly poor for those taking bupropion in the first 3 days of withdrawal. However, when 
nicotine smokers were examined during withdrawal, no differences were detected between 
bupropion (150-300mg) and placebo (Shiffman et al., 2000).  
 
 
 
Milnacipran 
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Milnacipran inhibits the reuptake of serotonin and noradrenaline (Bourin et al., 2005), but does not 
blockade histamine H1 or the α1-adrenoceptor site. It might be expected that this compound would 
be associated with REM suppression and less sedation, but RCTs are scarce. Uncontrolled studies 
suggest no long term effect on REM sleep, and improved sleep efficiency (Lemoine and Faivre, 
2004). 
 
Healthy participants  
(Poirier et al., 2004) demonstrated that milnacipran was associated with improvements in subjective 
sleep ratings (sleep latency, sleep quality and waking), but did not differ from placebo in this 
respect.  
 
Other psychotropic medications 
Since sleep disturbance is often found with antidepressants, particularly in the form of insomnia 
with SSRIs, hypnotic medications have been added to an antidepressant to offset the sleep problem. 
The addition of the novel antipsychotic risperidone has been found to reduce sleep disturbance in 
resistant depression (Ostroff and Nelson, 1999), but there is much more evidence for hypnotics. In 
one study of SSRI-treated depressed patients (Asnis et al., 1999), those receiving fluoxetine (≤ 
40mg), sertraline (≤ 100mg) or paroxetine (≤ 40mg), who reported significant insomnia, were 
entered into a double-blind phase where they were randomised to zolpidem (10mg) or placebo for 4 
weeks, followed by single-blind placebo for 1 week.  
 
Those receiving zolpidem demonstrated improved sleep (longer TST, better sleep quality, and 
reduced WASO) and significant improvements in subsequent daytime perceptions. In the single-
blind phase of placebo, the zolpidem group presented significant worsening of sleep, but no 
evidence of withdrawal effects. In another study (Londborg et al., 2000), depressed outpatients 
were randomised to fluoxetine (20mg) plus clonazepam (0.5-1mg), or fluoxetine plus placebo. 
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Significantly more patients showed improvements in sleep disturbance in the cotherapy group than 
with placebo, although sedation was reported more often with cotherapy than with placebo.  
 
Summary 
Antidepressants are associated with differing effects on sleep profiles, with variations between and 
within classes: sometimes there is conflicting evidence for individual compounds. The effect on 
sleep is related to pharmacological properties such as the degree of inhibition of serotonin or 
noradrenaline reuptake, the effects on 5-HT1A and 5-HT2 receptor sites, and actions at α1- and α2-
adrenoceptors, and histamine H1 sites. The effect that an antidepressant has on sleep is important 
because it may influence the clinician’s decision regarding which antidepressant to prescribe to 
which patient.  
 
There is much variation in the reported effects on sleep from TCAs. Amitriptyline (Hindmarch et 
al., 2000), trimipramine (Sonntag et al., 1996), nortriptyline (Hammack et al., 2002), dothiepin 
(Blacker et al., 1988) and doxepin (Hajak et al., 2001) have all been associated with sedation, while 
imipramine (Volkers et al., 2002) and desipramine (Shipley et al., 1985) are less likely to be linked 
with sedation, but have been associated with insomnia; the evidence is less clear with 
clomipramine. At the same time, amitriptyline (Rosenzweig et al., 1998), nortriptyline (Hammack 
et al., 2002) and (particularly) dothiepin (Wilson et al., 2002) have frequently been linked with 
poorer reports of daytime drowsiness. Improved subjective ratings of sleep have been reported with 
amitriptyline (De Ronchi et al., 1998), clomipramine (Lepine et al., 2000), imipramine (Ware et al., 
1989) and doxepin (Hajak et al., 2001).  
 
Clinician ratings of sleep (via HAMDS) have improved with amitriptyline (Versiani et al., 1999), 
clomipramine (Lepine et al., 2000), imipramine (Rosenberg et al., 1994), dothiepin (Corne and 
Hall, 1989) and doxepin (Feighner et al., 1986). EEG studies suggest that sleep length and 
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efficiency are increased, and nocturnal disturbances reduced, for amitriptyline (Casper et al., 1994), 
clomipramine (Eberhard et al., 1988), trimipramine (Wolf et al., 2001), nortriptyline (Reynolds, III 
et al., 1997) and doxepin (Hajak et al., 1996); although one study of nortriptyline suggested longer 
sleep latency (Hammack et al., 2002) and another found no improvement in total sleep time for 
amitriptyline (Raigrodski et al., 2001). Greater disturbance, and less sleep, is reported with 
imipramine (Volkers et al., 2002) and desipramine (Shipley et al., 1985). REM sleep suppression is 
reported with all TCAs except trimipramine (Riemann et al., 2002). Patients who report difficulty 
getting to sleep are more likely to benefit from amitriptyline, trimipramine, nortriptyline, dothiepin 
and doxepin. These patients are less likely to benefit from imipramine and desipramine.  
 
Not much data is available on sleep effects with MAOIs. In general, they are associated with greater 
nocturnal disturbance and shorter sleep times, with insomnia common (Winokur et al., 2001). 
MAOIs have been reported to significantly suppress REM sleep (Nolen et al., 1993). The few RCTs 
that were found during this review appear to support these findings. Nevertheless, subjective reports 
of sleep were favourable with tranylcypromine (Nolen et al., 1993) and isocarboxazid (Giller et al., 
1982). All the same, MAOIs appear to present few benefits for the troubled sleeper. The reversible 
MAOI moclobemide is less associated with REM sleep suppression, and appears not to effect sleep 
notably (Ramaekers et al., 1992).  
 
SSRIs are commonly associated with insomnia (Anderson et al., 2000), although occasionally 
daytime sleepiness has been reported with higher doses (Beasley Jr  et al., 1992). Despite this, 
patients’ subjective sleep reports whilst taking SSRIs are frequently positive, as are clinicians’ 
ratings. However, EEG studies frequently show greater fragmentation of sleep with SSRIs. REM 
sleep suppression is frequently found with these compounds.  In RCTs, prolonged sleep latency and 
reduced sleep time have been noted with sertraline (Jindal et al., 2003), fluoxetine (Gillin et al., 
1997), fluvoxamine (Wilson et al., 2000) and paroxetine (Hicks et al., 2002), particularly when 
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compared to placebo and against the sedative TCAs. However, patient-rated LSEQ scores have 
been shown to improve with citalopram (Leinonen et al., 1999), sertraline and fluoxetine (Aguglia 
et al., 1993), comparing well with TCAs in this respect, although not so well as some of the newer 
antidepressants.  
 
Clinician-rated HAMDS scores were improved in the trials that investigated citalopram (Mendels et 
al., 1999), sertraline (Lepine et al., 2000), fluoxetine (Winokur et al., 2003), fluvoxamine (Dalery 
and Honig, 2003) and paroxetine (Dunbar et al., 1993). It is unlikely that a patient with a history of 
sleep disturbance will benefit from SSRI treatment. There are few differences between SSRIs, 
unlike TCAs. Some studies suggest that sertraline and fluoxetine present similar improvements in 
LSEQ scores (Aguglia et al., 1993), while others show better improvement with sertraline (Bennie 
et al., 1995); sertraline was also shown to produce fewer reports of insomnia than fluoxetine. 
Fluvoxamine appears to be associated with less sleep disruption than paroxetine (Silvestri et al., 
2001).  
 
No general comments can be made about ‘other’ antidepressants, since their mode of action varies 
widely. Venlafaxine and reboxetine appear to be similar to SSRIs in REM sleep suppression and 
nocturnal disturbance (Luthringer et al., 1996), and to present similar improvements in clinician-
rated HAMD sleep scores (Cunningham et al., 1994). Trazodone has been found to have favourable 
sleep outcomes in a number of trials, showing better improvements in subjective sleep ratings than 
TCAs (Moon and Davey, 1988), and performing equally well against placebo with the hypnotic 
zolpidem in respect of insomnia and sleep time (Walsh et al., 1998).  
 
Nefazodone presents some of the more positive sleep outcomes of any antidepressant, frequently 
showing better sleep time and less disruption than SSRIs (Hicks et al., 2002). Mianserin was shown 
to be associated with greater improvements in LSEQ ratings than SSRIs, but with poorer 
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perceptions on waking (Perez and Ashford, 1990). Mirtazapine appears to compare well with TCAs 
on sleep time and nocturnal disturbance, with a quicker, but less sustained improvement profile 
(Bruijn et al., 1999). HAMD sleep scores have been shown to be better with mirtazapine than 
venlafaxine (Guelfi et al., 2001), and similar to fluoxetine (Winokur et al., 2003).  
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 Table 1: Effect of antidepressants on sleep: summary of randomised controlled trials 
See table footnotes for key to abbreviations 
       
Lead Author, Year 
 
Study dose Reference treatment Subjects N Duration Outcome, following treatment 
       
Amitriptyline       
Capaci, 2002 10-20mg Paroxetine 20-40mg Fibromyalgia 
patients 
40 8 weeks AMI sig improvement disturbed sleep wks 4 & 8 (p=.008; p<.001), PAR sig 
improved wk 8 (p=.002), AMI sig better than PAR at wks 4 & 8 (p=0.002; p<.001); 
AMI sig improvement non-refreshed sleep wks 4 & 8 (p=.008; p<.001), PAR sig 
improved wk 8 (p=.031), AMI sig better than PAR wk 8 (p=.011) 
Mercadante, 2002 25-50mg Placebo Cancer patients 16 2 weeks Drowsiness sig more intense with AMI vs. PLC (p=.036) 
Raigrodski, 2001 25mg/night Placebo Bruxism patients 10 4 weeks AMI did not increase TST or reduce EMG activity, compared to PLC 
Hindmarch, 2000 50mg Milnacipran 75mg 
Placebo  
Healthy volunteers  10 3 days AMI group showed sig increases in subjective ratings of sedation and difficulty 
waking (p<.05), compared to PLC; MIL not different to PLC 
Versiani, 1999 50-250mg Fluoxetine 20mg Depressed patients 157 8 weeks HAMDS reduced with both drugs, but sig more for AMI (-3.3) than FLX (-1.9; 
p<.001); daytime somnolence reported sig more often AMI (40.0%) than FLX 
(14.3%; p<.001) 
Hannonen, 1998 25-37.5mg 1: Moclobemide 450-
600mg; 2: Placebo 
Fibromyalgia 
patients 
130 12 weeks AMI sig improvement subjective sleep (p<0.001) & fatigue (p<0.01); MOC group 
no improvement, but PLC group also showed improvement in these ratings (p<.05) 
Moller, 1998 75-225mg Sertraline 50-150mg  Depressed patients 160 6 weeks AMI sig better improvements in HAMDS than SER (AMI -2.4; SER -1.8; p=.008) 
Rosenzweig, 1998 50mg 1: Befloxatone 10mg 
2: Placebo 
Elderly (65-85) 
healthy volunteers 
12 3 days AMI worsened subjective alertness (poorer ease of waking, p=0.002; poorer 
behaviour following waking, p=.009 – suggesting ‘hangover’ effect); BEF 
maintained alertness; no other subjective sleep variables affected 
Srisurapanont, 1998 Mean 57.7mg Lorazepam (mean) 2.1mg Opiate withdrawal 
patients 
27 5 days No difference between drugs on LSEQ ratings, except ease of waking (AMI 132.8, 
LOR 167.6; p=.047), suggesting poorer subjective waking for AMI 
Mertz, 1998 50mg/night Placebo Gastric patients 14 4 weeks AMI poorer SE, increased arousal, and reduced REM sleep, compared to PLC (no 
SWS) 
De Ronchi, 1998 50-100mg  Fluoxetine 20mg Depressed patients 65 10 weeks LSEQ sig increased for AMI (94.7) & FLX (108.6), no between-group differences 
Koh, 1997 30mg/night Placebo Rheumatic patients 100 2 weeks AMI group showed sig improvements in restful sleep, compared to PLC (p<.001) 
Kasper, 1997 Mean 21.6-
49.4mg 
Mirtazapine (mean) 94.2-
180.1mg 
Depressed patients 405 5-6 weeks No difference on HAMDS between drugs, but both showed decrease (AMI: 4.90 vs. 
1.74; MIR: 4.80 vs. 1.66; within-group significance not reported) 
Ataoglu, 1997 50mg Paroxetine 20mg  Fibromyalgia 
patients  
68 6 weeks Self-reported sleep perceptions improved at days 15, 30 & 45 for PAR (p<.01) and 
days 30 & 45 for AMI (p<.01); no between-group differences 
Staner, 1995 150mg Paroxetine 30mg Depressed patients 40 4 weeks Both drugs reduced REM sleep, but only PAR demonstrated an alerting effect 
Carette, 1995 25 mg Placebo Fibromyalgia 
patients 
22 8 weeks Groups only investigated in respect of NonREM parameters; neither group 
presented changes in NonREM after treatment 
Robbe, 1995 See paroxetine; AMI = active control in this pct     
Casper, 1994 100-250mg Imipramine 100-250mg Depressed patients 79 6 weeks Sig greater improvement in EMA & WASO for AMI, compared to IMI, wks 2 
(p=.008), 3 (p=.009) & 4 (p=.04); improvements earlier for AMI than IMI, but only 
in treatment responders; both groups reported less SL, EMA and WASO wk 1, 
regardless of treatment response (p<.001), only responders continued improvement 
by wk 4 (p=.003) 
Kerrick, 1993 50mg Placebo  Hip or knee 
arthroplasty patients 
28 3 days AMI or PLC used as adjunct to opiods in 3 day postop following arthroplasty;  SL 
ratings sig better in AMI group, compared to PLC (p<.025)  
 40 
  
Kerr, 1993 75mg Fluoxetine 20mg Elderly depressed 
patients 
66 7 weeks LSEQ scores improved both groups; AMI sig shorter SL wk 1 than FLX (p<.05), no 
other between-group differences (including no sig rating of ‘hangover’ for AMI, 
despite quick sedation at wk 1); however, LARS scores indicated that FLX patients 
less drowsy than AMI at wks 1 & 2 (p<.05) 
Kerkhofs, 1990 150mg  Fluoxetine 60mg Depressed patients 34 6 weeks Both groups sig decrease REM% (p<.001) and increase in REML (p<.001), but no 
between-group differences 
Zitman, 1990 75mg Placebo Chronic pain 
patients 
39 12 weeks AMI group ‘slept better’ from second week, compared to PLC; AMI pts slept for 
longer than PLC pts, sig so at wk 2 (p<.01) 
Hubain, 1990 100-225mg Alprazolam 4-9mg Severely depressed 30 6 weeks Both groups showed lengthened REML, and less REM time 
Ventafridda, 1988 25-75mg Trazodone 75-225mg  Chronic pain 
patients 
45 15 days Both groups showed increase in TST (approx 2 hrs per day; ns), but actual time in 
bed was sig more reduced in TRZ (4 hrs) than AMI (1.5; p=.005) 
Blacker, 1988 See trazodone, the main focus of this paper     
Skrumsager, 1986  150mg Femoxetine 600mg Depressed patients 81 6 weeks AMI group showed sig reduction in HAMDS; no such change with femoxetine 
Shipley, 1985 See Desipramine, the main focus of this paper     
       
Clomipramine       
Lepine, 2000 50-150mg Sertraline 50-200mg Depressed 
outpatients  
166 8 weeks LSEQ items sig increased from baseline in both groups (p<.001), but no sig 
between-group differences; HAMDS sig reduced for both groups (p value not 
specified), but no sig between groups differences  
Eberhard, 1988 25-150mg Maprotiline 50-150mg Depressed patients 52 6 weeks Sig improvement both groups sleep disturbance (p<.01); no between-group 
differences  
Lacey, 1977 25-75mg Placebo  Healthy volunteers 12 4 nights 
x2 
Randomly assigned to PLC then CLO 6 weeks later, or CLO then PLC;  CLO 
nights slightly more WMINS than PLC (ns); CLO nights sig less REM% (p<.001) 
than PLC (REM almost totally suppressed with CLO) 
       
Imipramine       
Volkers, 2002 Mean 220 mg Fluvoxamine (mean) 
201mg 
Depressed patients 52 4 weeks IMI more fragmentation of motor activity during sleep (p<.05) than FLUV 
Bruijn, 1999 Mean 235mg Mirtazapine (mean) 77mg Depressed 
inpatients 
107 4 weeks MIR  rapid improvements in sleep wk 2, normalising by wk 4; IMI more gradual 
improvement, exceeding MIR by wk 4 
Volz, 1997 100-150 mg Brofaromine 100-150mg Depressed patients 198 6 weeks Both groups similar reductions HAMDS  (IMI: 2.44/-1.16; BRO: 2.16/-1.46; ns) 
Sonntag, 1996 50-200mg Trimipramine 50-250mg Depressed 
inpatients (male)  
20 4 weeks TRIM sig increased TST, after 4 wks, sig reduced WMINS immediately and 
through to 4 wks, sig increased REM time immediately and through to 4 wks, sig 
reduced REML immediately, but increased again to 4 wks (ns); IMI sig increased 
SL by end of 4 wks, sig increased stage 1 sleep immediately and through to 4 wks, 
sig reduced REM time immediately, but sig increased again to 4 wks, sig increased 
REML immediately, but sig reduced this again to 4 wks; no p values stated 
Van Laar, 1995 See nefazodone      
Rosenberg, 1994 50-150mg 1. Citalopram 10-30mg 
2. Citalopram 20-60mg 
Depressed patients 
in primary care 
472 6 weeks All groups showed reduction in HAMDS, but not sig between groups 
Cassano, 
1994(Cassano et al., 
1994)  
25-250mg 1: Alprazolam 1-10mg 
2: Placebo 
Panic/agoraphobia 
patients 
1168 8 weeks Sig more sedation for ALP (58%) than IMI (31%) or PLC (21%); sig more 
insomnia for IMI (22%) than ALP (3%) and PLC (12%) 
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Ware, 1989 75-200mg Trimipramine 75-200mg Depressed patients 
presenting insomnia 
30 4 weeks Both groups reported shorter SL initially, but IMI increasing SL after 7 days, TRIM 
continued improving; TST increased TRIM, but decreased IMI (p=.02), TST and 
SE sig improved for TRIM (P<.01), WASO greater for IMI than TRIM (P<.01), 
REML sig increased for IMI, TRIM no change, REM% sig decreased for IMI 
(P<.01), TRIM no change 
       
Trimipramine       
Riemann, 2002 Mean 100mg 1: Lormetazepam 
2: Placebo 
Insomnia patients 55 4 weeks TRIM did not suppress REM sleep; LOR decreased WMINS and SWS, increased 
REM sleep, compared to PLC; sleep returned to normal when switched to PLC 
Wolf, 2001 150mg Fluoxetine 20mg Depressed geriatric 
patients 
19 6 weeks TRIM sig higher SE (p<.05), longer TST (p<.05), shorter WASO (p<.01); FLX 
decreased REM% (p<.01) increased REML (p<.05) 
Sonntag, 
1996(Sonntag et al., 
1996)  
See imipramine      
Ware, 1989 See imipramine      
       
Desipramine       
Kupfer, 1991 100-200mg Fluvoxamine 200mg Depressed 
inpatients 
35 4 weeks DES sig reduced SL day 1, sig increased by day 7 to end (p=.01), sig increased 
stage 2 sleep day 1 to end (p<.001), sig reduced REM% at day 1, increased day 2 to 
end (p<.001), sig increased REML at day 1, decreased  day 2 to end (p<.001); FLX 
sig increased SL at day 1 (p<.001), decreased  day 7 to end (ns), sig increased 
WMINS at day 1 to end (p<.001), sig reduced SE at day 1, returning to baseline by 
day 7 (p<001), sig reduced REM% by day 1, increasing at end (p<.001), sig 
increased REML by day 1, still further day 2, reduced from day 7  to end (p<.001); 
groups sig differed on SL (FLX>DES), SE (DES>FLX) and REML (FLX>DES) 
Shipley, 1985 1: 50mg 
2: 150mg 
3: 150-250mg 
Amitriptyline 50-150mg Depressed 
inpatients 
33 4 weeks Compared to baseline, DES 50mg sig more WASO (P<.01), more stage 2 sleep 
(p<.01), less REM% (p<.001), greater REML (p<.001); DES 150mg sig less 
REM%, greater REML (all p<.001); DES 150-250mg sig more stage 1 sleep 
(p<.05), stage 2 sleep (p<.01), less REM% (p<.001), greater REML (p<.001); 
compared to AMI, DES sig more WASO (p<.01), more WMINS (p<.01), less TST 
(p<.05), poorer SE (p<.01) less REM time (p<.01) 
       
Nortriptyline       
Hammack, 2002 100mg Placebo Patients with severe 
pain 
51 9 weeks TST increased by 0.5 hours with NOR, decreased by 0.3 hours with PLC (p=.02); 
NOR more likely to report sleepiness as a side effect than PLC (ns; p=.09) 
Taylor, 1999 Mean 70.8mg Placebo Elderly bereaved 
depressed patients 
27 6 months NOR decreased REM time and increased REM density; no change PLC; REM sleep 
NOR group reverted to baseline after withdrawal; subjective SQ returned to normal 
Reynolds, 1997 80-120 ng/mL Placebo Elderly recurrent 
depressed patients 
40 1 year  NOR sig longer SL (p=.02), longer REML (p=.01), less REM proportion (p=.001) 
greater REMD (p<.001) more REM production throughout (p<.001) 
       
Dothiepin        
Wilson, 2002 75-150mg  1: Fluoxetine 20mg 
2: Placebo 
Healthy volunteers 
(male) 
12 5 weeks Both active drugs less REM sleep time than PLC day 10 (p=.001) & day 36 (p=.04); 
FLX group longer REML than PLC and DOT day 10 (p=.003); both active groups 
longer REML than PLC day 36 (p=.03); DOT group poorer SE than FLX & PLC 
day 36 (p=.04); FLX group more WMINS than DOT day 10 (p=.03) 
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Stephenson, 2000 150mg  Fluoxetine 20mg Depressed patients 125 6 weeks No between-group differences on LSEQ scores, but disturbed sleep/drowsiness side 
effects reported more often in DOT group 
Wilson, 2000 See fluvoxamine       
Ramaekers, 1995 75-150mg 1: Fluoxetine 20mg 
2: Placebo 
Healthy volunteers 18 22 days DOT reported increased difficulty waking days 1-3 (p=.043), FLX on days 17-21 
(p=.02); DOT days 1-3 estimated 43 minutes longer TST than PLC (p=.02) 
Ferguson, 1994 150mg/night Doxepin 150mg/night 
Placebo  
Depressed patients 579 10 weeks HAMDS sig reduced for DOT and DOX, compared to PLC (p<.05) 
Corne, 1989 75-100mg Fluoxetine 40-60mg Depressed patients 
in primary care 
100 6 weeks No between-group differences on HAMDS, but tiredness/drowsiness side effects 
reported more often in DOT group and response quicker for DOT 
Blacker, 1988 See trazodone      
       
Doxepin       
Hajak, 2001 25-50mg Placebo  Insomnia patients  47 4 weeks DOX sig increased SE compared to PLC (p<.05); DOX sig improved SQ (P<.001); 
but, pts with severe insomnia rebound (after treatment withdrawal) were sig more 
likely to have taken DOX than PLC 
Hajak, 1996 25mg Placebo Insomnia patients 
Healthy volunteers 
10 
5 
3 weeks DOX sig improved SL, TST, and WMINS in both study groups, compared to PLC 
Ferguson, 1994 See dothiepin      
Feighner, 1986 100-225mg Bupropion 300-450mg Depressed patients 147 14 weeks HAMDS sig improved in DOX, compared to BUP (p<.05) 
Hameroff, 1984 Mean 200mg Placebo Pain patients  60 6 weeks Sig improvements in sleep for DOX, relative to PLC 
Hameroff, 1982      Same dataset as Hameroff, 1984 
       
Lofepramine No RCTs found      
       
Phenelzine No RCTs found      
      
Tranylcypromine      
Nolen, 1993 20-100mg Brofaromine 50-250mg Depressed patients 39 4 weeks Both treatments sig increase REML (P=.02), more so BRO, slightly reduced stage 1 
sleep (ns), sig increased stage 2 (p<.001), increased stage 3 (ns), and sig reduced 
stage 4 (p=.001); SWS reduced overall and approached sig (p=.07); both groups sig 
reduced REM (p<.001), particularly TRAN; shorter TST reports, more WASO and 
waking more tired with BRO, SL longer, but sleep deeper and more refreshed with 
TRAN (p=.02) 
       
Isocarboxazid       
Giller, 1982 20mg Placebo Depressed 
outpatients  
30 3 weeks No HAMDS score changed overall, although those who responded best to active 
drug tended to report less sleep disturbance 
       
Moclobemide       
Sogaard, 1999 See sertraline      
Hannonen, 1998 See amitriptyline      
Dingemanse, 1992 450mg  Toloxatone 200-400mg  Healthy volunteers 12 8 days No differences detected on sleep variables between groups  
Ramaekers, 1992 200mg 1: Mianserin 10mg 
2: Placebo 
Healthy volunteers 17 8 days No differences in reports of SQ, but MIA group showed increased sleep, and 
reported daytime drowsiness/fatigue; MOC appeared to have little effect on sleep 
Lemoine, 1992 450mg Toloxatone 1000mg Depressed patients 268 4 weeks Sig more MOC group showed improved sleep patterns than TOL  
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Citalopram       
Mendels, 1999 20-80mg Placebo  Depressed patients, 
with melancholia 
180 4 weeks CIT group sig improvement in HAMDS relative to PLC (p<.05), but somnolence 
reported as side effect in twice as many CIT group as PLC 
Leinonen, 1999 See mirtazapine      
Rosenberg, 1994 See imipramine      
       
Escitalopram No RCTs found      
       
Sertraline       
Jindal, 2003 Mean 142mg Placebo Depressed patients 47 12 weeks Compared to PLC, SER increased SWS 1st sleep cycle (ns), decreased SWS 2nd 
cycle (p=.05), longer REML (p<.001); SER group showed increase SL (ns), but no 
worsening SE; subjective (PQSI) ratings showed sig improvements for both groups 
(p<.001), but no between-groups differences  
Paul, 2002 50-150mg Placebo Healthy volunteers 19 5 weeks SER group showed more insomnia than PLC (p=.002), more nocturnal awakenings 
(p=.007) and more problems returning to sleep (p>.001) 
Fava, 2002 50-200mg 1: Fluoxetine 20-60mg 
2: Paroxetine 20-60mg 
Depressed patients 284 16 weeks No between-group differences in respect of worsening or improvement of insomnia 
Kroenke, 2001 Mean 72.8mg 1: Paroxetine mean 
23.5mg 
2: Fluoxetine mean 
23.4mg 
Depressed patients 
(primary care) 
573 9 months All groups increase (improvement) MOS sleep scores, but no between-group 
differences 
Lepine, 2000 See clomipramine      
Sogaard, 1999 50-100mg  Moclobemide 300-450mg Atypical depressed 
patients 
190 12 weeks SER group showed sig improvement on LSEQ Item 4 (integrity of behaviour on 
waking); no other sleep differences between groups 
Sechter, 1999 50-150mg Fluoxetine 20-6mg Depressed 
outpatients 
238 24 weeks SER near-sig improvement LSEQ scores relative to FLX at 18 wks (p=.08; p=.13 at 
24 wks); sleep & rest item of SIP sig improvement in favour of SER (p=.04) 
Moller, 1998 See amitriptyline      
Bennie, 1995 50-100mg Fluoxetine 20-40mg Depressed 
outpatients  
286 6 weeks Both groups showed sig improvement in LSEQ scores (p<.05), across all items; 
tendency for SER to present less difficulty in getting to sleep than FLX, while FLX 
tended to feel better on waking than SER, but no between-group differences overall 
Aguglia, 1993 Mean 72mg Fluoxetine mean 28mg Depressed 
outpatients 
108 8 weeks Both groups showed sig improvement in LSEQ scores, but there was no difference 
between the groups; although FLX group reported more insomnia than SER 
       
Fluoxetine       
Winokur, 2003 20-40mg Mirtazapine 15-45mg Depressed patients 
with insomnia 
19 8 weeks No between-group differences HAMDS; both sig reduction  wk 2  to wk 8 (p<.05); 
MIR better improvement SL & TST, compared to FLX; trend better improvement 
SE for MIR; FLX non-sig reduction SWS, increased WASO, increased REML, 
reduced REM time (p=.033), non-sig reduction SWS; MIR showed sig reduction SL 
(p=.0015), longer TST (p=.04), better SE (p=.0004), less WASO (p=.0008) 
Dalery, 2003 20mg Fluvoxamine 100mg Depressed 
outpatients 
184 6 weeks Subjective sleep did not differ between  groups until wk 4, then SQ favoured FLUV 
(ns); HAMDS improvement was sig greater with FLUV than FLX at wks 4 and 6 
Wilson, 2002 See dothiepin      
Fava, 2002 See sertraline      
Kroenke, 2001 See sertraline      
Stephenson, 2000 See dothiepin      
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Wolf, 2001 See trimipramine      
Flament, 1999 See sertraline      
Sechter, 1999 See sertraline      
Wheatley, 1998 20-40mg Mirtazapine 15-60mg Depressed patients  6 weeks No significant between-group differences  
De Ronchi, 1998 See amitriptyline      
Rush, 1998 20-40mg Nefazodone 100-500mg Depressed 
outpatients 
125 8 weeks SE sig increased with NEF (p=.05), sig reduced with FLX (p=.05), FLX sig poorer 
than NEF (p=.01); WASO sig reduced with NEF (p=.01), sig increased with FLX 
(p=.01), FLX sig poorer than NEF (p=.01); SWS sig reduced both groups (p=.01); 
REM time sig reduced with FLX (p=.01), sig increased NEF (p=.01), NEF sig 
longer than FLX (p=.01); improvements sig greater for NEF than FLX on HAMDS 
(both improved) and sleep items on IDS-C and IDS-SR 
Bennie, 1995 See sertraline      
Gillin, 1997 20mg Nefazodone 200-400mg Depressed patients 43 8 weeks FLX sig decreased SE and REM time, increased WASO and REML; NEF sig 
decreased %AMT, but did not alter SE or WASO, REM time or REML;  both 
groups showed sig improvement in some clinician- and patient-rated sleep 
disturbance scores, but NEF group generally improved more than FLX group 
Armitage, 1997 20-40mg Nefazodone 200-500mg Depressed 
outpatients with 
insomnia 
43 8 weeks NEF increased SE, reduced WASO & %AMT; FLX increased WASO & REML, 
reduced REM time; NEF increased REM sleep, decreased REML; NEF greater SE, 
less WASO, less %AMT more REM sleep, shorter REML than FLX; sig greater 
improvement subjective sleep disturbance NEF than FLX; NEF reported better SQ 
Satterlee, 1995 20mg Placebo Depressed 
outpatients 
89 8 weeks HAMDS scores were improved for FLX relative to PLC (but ns); HAMDS scores 
worsened more often with PLC than FLX (ns); HAMDS scores improved more 
often with FLX than PLC (ns) 
Nofzinger, 1995 See bupoprion      
Ramaekers, 1995 See dothiepin      
Vasar, 1994 20mg Placebo  Healthy volunteers 12 6 days FLX sig increased SL (p=.03), reduced SE (p=.03), increased REML (p=.04), 
reduced REM% (p=.01), increased stage 2% (p=.03), increased stage 3% (p=.02), 
PLC ns; no within/between-group differences subjective sleep measures 
Wolfe, 1994 20mg  Placebo Fibromyalgia pts  42 6 weeks SQ improved for FLX group (p=.03) 
Kerr, 1993 See amitriptyline      
Aguglia, 1993 See sertraline      
Kerkhofs, 1990 See amitriptyline      
Corne, 1989 See dothiepin      
       
Fluvoxamine       
Dalery, 2003 See fluoxetine      
Volkers, 2002 See imipramine      
Silvestri, 2001 100mg Paroxetine 20mg Healthy volunteers 14 1 month PAR disrupted sleep more than FLUV; REM sleep suppressed (especially for 
FLUV) rebounded during withdrawal (especially for PAR) 
Wilson, 2000 100mg Dothiepin 100mg Healthy volunteers 12 3 days FLUV shorter TST than DOT & PLC, more WMINS than PLC, poorer SE than 
DOT or PLC, more WASO than DOT or PLC, shorter SL than PLC, less time in 
REM sleep than PLC; DOT more SWS than PLC and FLUV, longer REML than 
OT or PLC; FLUV reported poorer SQ than DOT and PLC; DOT group reported 
more difficulty waking than FLUV and PLC, FLUV superior to PLC 
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Kupfer, 1991 See desipramine      
Perez, 1990 100-300mg Mianserin 60-180mg Depressed patients 63 6 weeks LSEQ rating of SL sig better for MIA than FLUV at days 3 & 5 (p<.05), better 
rating of feelings on waking for FLUV than MIA at day 3 (p<.05); MIA better 
subjective SL, feeling more drowsy & fewer wakings than FLUV, FLUV easier 
waking up than MIA (all ns) 
       
Paroxetine       
Ridout, 2003 20mg 1: Mirtazapine 15-30 mg 
(comparator; MIRC) 
2: Mirtazapine 15mg bid 
(positive control; MIRPC) 
Healthy volunteers  12 10 days PAR and MIR reported sig increased sedation (LARS); sig lengthening LSEQ SL 
PAR vs  MIRC day 2, not PLC; sig reduction SL MIRPC vs PLC; SL sig higher 
PAR vs other treatments day 3;  SL sig lower MIRPC vs other treatments wk 4; 
LSEQ SQ sig poorer PAR vs PLC, sig better both MIR groups vs PLC; MESS  
indicated increased sleepiness with MIRPC days 1 and 2, with no other sig effects 
Schatzberg, 2002 20-40mg Mirtazapine 15-45mg Elderly depressed 
patients (65+) 
246 8 weeks HAMDS score sig lower MIR than PAR wks 1 (p<.001), 2 (p=.006), and 6 
(p=.005); ns wk 8 (p=.062) 
Hicks, 2002 20-40mg Nefazodone 400-600mg Depressed patients 40 8 weeks TST, SE and WMINS worsened PAR, improved NEF, early in treatment, tended 
towards baseline by wk 8; WASO sig worse by wk 8 PAR; REML sig increased, 
REM time sig reduced PAR; NEF slightly decreased REML but increased REM 
time; subjective data (SMHSQ) indicated greater improvements in SQ and depth of 
sleep for NEF; no LSEQ factor showed sig between-group differences 
Capaci, 2002 See amitriptyline      
Fava, 2002 See sertraline      
Kroenke, 2001 See sertraline      
Silvestri, 2001 See fluvoxamine      
Ruwe, 2001 40mg 1: Mirtazapine 30mg 
2: Combination MIR/PAR 
(CT) 
Healthy volunteers 24 6 days LSEQ: CT got to sleep more easily and quickly, felt more drowsy at sleep onset 
than PAR alone; CT group felt less drowsy at sleep onset than MIR alone; no 
between-group differences SQ; CT tended to have greater difficulty waking than 
PAR alone; no different to MIR alone; CT felt more tired on waking, PAR alone; no 
different to MIR alone 
Kiev, 1997 See fluvoxamine      
Sharpley, 1996 30mg Nefazodone 400mg Healthy volunteers 37 17 days PAR reduced REM sleep, increased REML and WASO, reduced TST and SE; NEF 
did not alter REM sleep and had little effect on sleep continuity 
Staner, 1995 See amitriptyline      
Robbe, 1995 1: 20mg 
2: 40mg 
1: Amitriptyline 75mg  
2: Placebo 
Healthy volunteers 16 8 days AMI group showed severe drowsiness, but this disappeared after 1 week; PAR 20 
mg had no effect on sleep; PAR 40 mg group showed poorer SQ 
Wade, 1993 15-30mg am vs. pm dosing Depressed patients 91 6 weeks HAMDS sig better for am dosing; trend towards better LSEQ scores for am dosing 
Dunbar, 1993 10-50mg Placebo  Depressed patients 336 6 weeks HAMDS scores sig more reduced for PAR than PLC at each week of trial (p<.05) 
Dorman, 1992 15mg Mianserin 30mg Elderly depressed  60 6 weeks 6 out of 10 LSEQ scores sig improved PAR, 1 factor sig increased MIA (p<.05); 4 
of factors worsened MIA, mostly re poorer waking (ns) 
Claghorn, 1992a 10-50mg Placebo Depressed patients 336 6 weeks Same dataset as Dunbar, 1993 
Claghorn, 1992b 10-50mg Placebo Depressed patients 336 6 weeks Same dataset as Dunbar, 1993 
Kiev, 1992 20mg Placebo Depressed patients  81 6 weeks Sig greater decrease in HAMDS for PAR (-2.41) than PLC (-0.81; p=.001) 
       
Maprotiline       
Edwards, 1983 See mianserin      
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Venlafaxine       
Guelfi, 2001 75-375mg  Mirtazapine 15-60mg Depressed patients  157 8 weeks MIR sig better HAMDS than VEN at all time points (p=.03) 
Luthringer, 1996 Up to 225mg Placebo  Depressed 
inpatients 
24 1 month VEN sig less REM time than PLC wk 1 & month 1,VEN sig reduced REM wk 1 
(p<.05); REML sig longer VEN than PLC at both time points, VEN sig increase 
REML wk 1 (p<.01); VEN more WASO than PLC, sig so month 1 (p<.05) 
Cunningham, 1994 25-200mg 1: Trazodone 50-500mg 
2: Placebo 
Depressed patients 225 6 weeks HAMDS scores reduced for all groups by wk 6; TRZ sig more than VEN and PLC; 
VEN HAMDS remained higher PLC 
       
Reboxetine No RCTs found      
       
Trazodone        
Le Bon, 2003 100mg Placebo  Alcohol dependent 
patients 
16 4 weeks TRZ increased SE immediately through to 4 weeks; no improvement for PLC;  TRZ 
also improved WASO, %AMT, and non-REM sleep 
Saletu-Zyhlarz, 2001 100mg Placebo Insomnia patients 
with dysthymia  
11 3 nights TRZ associated with sig increase in SWS, increase in REML and decrease in 
REM% (p<.05) 
Mashiko, 1999 50, 75, 100mg Dose ranging Depressed patients 
with insomnia  
75 4 weeks TRZ 50mg & 75mg sig better improvement HAMDS and HAMAS; 50mg sig better 
than 100mg; self-rated TST sig longer for 50mg vs. 100mg, and 75mg vs. 100mg 
Walsh, 1998 50mg 1: Zolpidem 10mg 
2: Placebo 
Primary insomniac 
patients 
306 2 weeks Both groups sig better ratings ease falling asleep (p=.005), WASO (p=.04), WMINS 
(p=.002) & SQ (p=.003) than PLC, no differences TRZ vs ZOL; SL decreased & 
TST increased ZOL and TRZ  (p<.05), SL sig shorter ZOL than TRZ (p=.037) 
Ware, 1994 100mg 1: Nefazodone 200mg 
2: Buspirone 10mg  
3: Placebo  
Healthy volunteers 12 3 nights TRZ sig fewer WASO than PLC; NEF sig less % stage 2 sleep than all other 
groups, sig less stage 3% than TRZ and BUS; NEF sig more REM% than PLC, but 
TRZ & BUS sig less REM% than PLC; TRZ & BUS sig longer REML than NEF 
and than PLC (all sig post-hoc comparisons to p=.05) 
Weisler, 1994 150-400mg Bupropion 225-450mg Depressed patients 124 6 weeks HAMDS scores sig improved for TRZ at days 7 (p<.001) and 14 (p<.05)  
Nierenberg, 1994 50-100mg Placebo  Depressed patients, 
with insomnia  
17 11 days TRZ sig lower (better) PSQI TST score (p=.003), sig lower overall score (p=.01) 
than PLC, TRZ near sig lower scores than PLC on SQ & SL (p=.06);  Y-NH HDSI 
sleep scores sig better for TRZ than PLC  middle insomnia (p=.03), late insomnia 
(p=.005) & overall sleep scores (p=.008); more pts improved with TRZ than PLC 
on PQSI (p=.004) and Y-NH HDSI sleep scores (p=.008) 
Cunningham, 1994 See venlafaxine      
Moon, 1988 150mg (night) Mianserin 30-60mg 
(night) 
Depressed patients 39 6 weeks Both groups showed sig improvements on LSEQ factors for ease of getting to sleep, 
sleep quality, ease of waking, and feelings upon waking (p<.0001), but no sig 
differences between them; TRZ improved at faster rate than MIA 
Blacker, 1988 150mg Amitriptyline 75-100mg 
Dothiepin 75-150 mg 
Mianserin 30-75mg 
Depressed patients 227 6 weeks All groups showed improved ease of getting to sleep and quality of sleep; this was 
immediate, although greatest for TRZ and DOT (p values not specified); feelings 
upon awakening were impaired in all groups until day 7, when these measures 
improved (in all groups except MIA, where improvement started at day 14) 
       
Nefazodone        
Hicks, 2002 See paroxetine      
Rush, 1998 See fluoxetine      
Feighner, 1998 100-600mg Placebo Depressed patients 120 6 weeks HAMDS scores sig better improved with NEF (-2.3) than PLC (-1.1; p<.01) 
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Vogel, 1998 200-400mg Placebo Healthy volunteers 22 16 days REM time, REML, REMD & REM% all remained unchanged, relative to baseline 
and PLC; TST sig less NEF than PLC day 1 (P<.05), normalised by day 2; WMINS 
sig more with NEF than PLC day 1 (p<.05) 
Gillin, 1997 See fluoxetine      
Armitage, 1997 See fluoxetine      
Sharpley, 1996 See paroxetine      
Van Laar, 1995 See imipramine 1:Nefazodone 100mg; 2: 
200mg; 3: Placebo 
Healthy volunteers 24 1 week SL sig greater for NEF 100mg and NEF 200mg, but not IMI, than PLC (p<.05) on 
day 1; no sig differences by day 7 
Ware, 1994 See trazodone      
       
Mianserin       
Ramaekers, 1998 15-60mg Mirtazapine 15-60mg Healthy volunteers 18 16 days Subjective estimates TST increased MIR and MIA throughout (p<.001), no 
between-group differences; SQ rated better MIR than MIA (p=.021); drowsiness 
was reported sig more often with MIR and MIA, compared to PLC (p=.015) 
Dorman, 1992 See paroxetine      
Ramaekers, 1992 See moclobemide      
Perez, 1990 See fluvoxamine      
Blacker, 1988 See trazodone      
Moon, 1988 See trazodone      
Costa, 1985 10-20mg Placebo Depressed women  73 4 weeks MIA reduced HAMDS, by end of trial; not PLC  
Levin, 1985 30-60mg Nomifensine 75-150mg 
and clobazam 22.5-45mg  
Depressed patients 40 3 weeks MIA group showed sig greater reduction in HAMDS (p<.05) than co-therapy 
Granier, 1985 30mg Nomifensine 50mg Depressed patients 61 4 weeks MIA greater improvement in HAMDS scores than nomifensine (p<.05)  
Van Moffaert, 1983 30mg Melitracen 30mg and 
flupentixol 1.5mg 
Anxious depressed 
patients 
90 4 weeks MIA greater improvement in insomnia factor of HAMD than co-therapy, at wks 1 
(p=.02) and 4 (p<.01) 
Edwards, 1983 30-90mg  1: Maprotiline 75-225mg 
2: Placebo 
Depressed 
outpatients 
58 6 weeks MIA sig better than PLC at reducing early insomnia day 14 (p<0.05), no other sig 
between-group differences HAMDS; no sig between-group differences LSEQ, but 
all sig reduced throughout (including PLC) 
Smith, 1978 30mg Placebo Manic-depressive 
psychosis depressed 
39 2 weeks MIA group sig improvements nurse-observed TST, compared to PLC, wks 1 
(P<.005) and 2 (p<.05); patient-rated estimates of TST sig improved MIA vs PLC 
wks 1 (p=.02) and 2 (p<.01); self-rated SL shorter MIA than PLC wk 1 (p<.01); pts 
woke sig later with MIA than PLC wks 1 (p<.01) and 2 (p<.05) 
       
Mirtazapine        
Winokur, 2003 See fluoxetine      
Ridout, 2003 See paroxetine      
Aslan, 2002 30mg  Placebo Healthy young 
volunteers 
20 3 nights MIR improved sleep continuity, compared with PLC, increased SE, decreased 
WASO and WMINS; SWS time increased; no sig effect on REM sleep 
Schatzberg, 2002 See paroxetine      
Guelfi, 2001 See venlafaxine      
Radhakishun, 2000 1: 30mg  
2: 15mg wk1, 
30mg wk2 
Dose ranging (fixed dose, 
FD vs. escalating dose 
ED) 
Depressed patients  140 2 weeks LSEQ ‘getting to sleep; GTS’ improved both groups, similar between  groups until 
wk 2, when GTS for FD sig better than ED (p=.021); TST estimates increased both 
groups, but FD exceeded ED wks 1 (p=.01) and 2 (p=.04); sig fewer FD pts than 
ED reported middle insomnia (p=.042) and early insomnia (p=.008) by wk 2 
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Bruijn, 1999 See imipramine      
Leinonen, 1999 15-60mg   Citalopram 20-60mg Depressed patients 270 8 weeks MIR group showed faster ‘improvement of sleep’, SQ and improved alertness 
following awakening on  LSEQ, relative to CIT 
Wheatley, 1998 See fluoxetine      
Kasper, 1997 See amitriptyline      
       
Nomifensine       
Levin, 1985 See mianserin      
Granier, 1985 See mianserin      
Fann, 1984 See imipramine      
       
Bupoprion       
Ott, 2002 150-400mg Placebo  Depressed patients 20 1 week No between-group differences, at 1 week relative to baseline; but BUP responders 
showed increase REML, non-responders showed decrease – a sig relationship  
Haney, 2001 300mg Placebo  Marijuana 
withdrawal patients 
10 4 weeks In withdrawal phase, problems with sleep were worse for BUP than PLC, 
particularly during first 6 fays of withdrawal; SMHSQ ‘difficulty sleeping’ and TST 
were sig poorer with BUP between days 1-3 (p<.005) and days 4-6 (p<.01)  
Shiffman, 2000 1: 150mg 
2: 300mg 
Placebo Non-depressed 
smokers 
91 2 weeks No differences found between BUP and PLC regarding HAMDS scores on nicotine 
withdrawal  
 
Nofzinger, 1995 Mean 25mg 1: Fluoxetine mean 428 
mg 
2: CBT 
Depressed patients 
(male) 
18 Up to 17 
weeks 
SE increased for all groups, but particularly for BUP (p<.05);  REML increased 
with CBT, dramatically increased for FLX, but decreased for BUP (p<.0001), 
REM% was unchanged with CBT and FLX, but increased with BUP (p<.01) 
Feighner, 1986 See doxepin      
Fabre, 1983 300-600mg Placebo Depressed inpats 75 4 weeks Effects on sleep between the groups were limited 
       
Milnacipran       
Poirier, 2004 50mg Placebo  Healthy volunteers  20 2 weeks Subjective sleep ratings (adapted from LSEQ) improved but no between-group 
differences 
Hindmarch, 2000 See amitriptyline      
       
 
Medication abbreviations: ALP Alprazolam ; AMI Amitriptyline; BRO Brofaromine; BUP Bupropion; BUS buspirone; CIT Citalopram; CLO Clomipramine; DES Desipramine; DOT Dothiepin; DOX 
Doxepin; FLUV Fluvoxamine; FLX Fluoxetine; IMI Imipramine; MIA Mianserin; MIL Milnacipran; MIR Mirtazapine; NEF Nefazodone; NOR Nortriptyline; PAR Paroxetine; PLC Placebo; SER Sertraline; 
TOL Toloxatone; TRAN Tranylcypromine; TRIM Trimipramine; TRZ Trazodone; VEN Venlafaxine; ZOL Zolpidem  
 
Other abbreviations: %AMT percentage of awake and movement time; CBT Cognitive behaviour therapy; EMA Early morning awakening; EMG Electromyogram (muscle activity); HAMAS Hamilton Rating 
Scale for Anxiety, Sleep Scores; HAMDS Hamilton Rating Scale for Depression, Sleep Scores; IDS-C Inventory for Depressive Symptomatology (Clinician-rated); IDS-SR (self rated); LARS Line Analogue 
Rating Scale for Sedation; LSEQ Leeds sleep evaluation questionnaire; MESS Milford Epworth sleepiness scale; MOS Medical Outcome Study scale; PQSI Pittsburgh Sleep Quality Index; PSG 
Polysomnography; REM Rapid Eye Movement Sleep; REMD REM density; REML REM Latency; REM% proportion time in REM sleep; SE Sleep efficiency; SIP Sickness Impact Profile; SL Sleep Latency; 
SMHSQ St Mary’s Hospital Sleep Questionnaire; SQ Sleep Quality; SWS Slow Wave Sleep; TST Total Sleep Time; WASO Wakings After Sleep Onset; WMINS Length of those wakings; Y-NH HDSI Yale-
New Haven Hospital Depression Symptom Inventory 
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